Key Highlights
- Harrow (NASDAQ:HROW) was trading up 6.54% at USD 30.15 on Friday, November 13, 2026, in market data, and no company announcement dated November 12 or 13 explaining the move was found.
- Third-quarter Revenue was USD 99.3 million, up 39%, with branded product sales up 62% to USD 83.5 million and compounding revenue down 21% to USD 15.8 million.
- The full-year adjusted EBITDA outlook was cut to a floor of more than USD 40 million from a prior range of USD 80 million to USD 100 million, per a published summary.
- Revenue guidance of USD 350 million to USD 365 million was reaffirmed, while nine-month Operating Cash Flow was an outflow of USD 27.4 million against an inflow of USD 35.5 million.
Third-Quarter Report Is the Latest Verified Catalyst
No company announcement explaining Friday's move was found, so the article rests on the most recent verified news. Harrow (NASDAQ:HROW) reported third-quarter 2026 results on November 9, 2026, according to a published summary of the filing that has not been cross-checked against the 8-K itself. A published report said shares rose 15.85% on November 10; that is single-source and unconfirmed. The company is a US ophthalmic pharmaceutical Business that sells branded eye-care medicines and also runs a compounding pharmacy unit. Revenue reached USD 99.3 million, up 39%, driven by branded sales of USD 83.5 million, up 62%, while compounding revenue fell 21% to USD 15.8 million.
Why a Lower EBITDA Floor Matters to the Story
The headline number is the guidance change. The full-year 2026 adjusted EBITDA outlook was reset to a floor of more than USD 40 million, down from USD 80 million to USD 100 million, with the summary citing first-half shortfalls, gross Margin pressure and higher research spending. Management called the figure a floor, not a forecast. GAAP Net Income was USD 9.8 million, helped by a USD 5.0 million litigation settlement gain, so it includes a one-off item. Revenue guidance of USD 350 million to USD 365 million was reaffirmed, which means the cut is about profitability, not sales.
Receivables Build and Debt Load Are the Pressure Points
Cash generation is the weaker side. Nine-month operating cash flow was an outflow of USD 27.4 million versus an inflow of USD 35.5 million a year earlier, as receivables built to USD 155.3 million. Notes payable were about USD 293 million against stockholders' Equity of USD 28.8 million, a thin cushion if collections slow. Growth in branded products can raise sales faster than cash arrives, and compounding revenue is shrinking. Because the share price is above USD 30 after a double-digit rise earlier in the week, further moves can reverse quickly. The next markers are whether gross margin stabilizes and whether receivables convert into cash in the fourth quarter.
Where Things Stand
Harrow (NASDAQ:HROW) can hold a 6.54% gain only if the market keeps weighing 39% revenue growth and reaffirmed revenue guidance more heavily than the lower EBITDA floor, and that cannot be known from one session. No company announcement explains Friday's move, so it may reflect follow-through after the November 9 report. The verified risks are weaker operating cash flow, receivables of USD 155.3 million and notes payable of about USD 293 million. Watch collections, gross margin and the fourth-quarter update.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...